Adam Scott Levy sold $155k of MLYS
CFO and Secretary at Mineralys Therapeutics, Inc.. 10,758 shares at an average of $14.45, traded Jul 11, 2025, filed Jul 15, 2025.
Score components
- +22RoleCFO
- +11Trade size$155k at market
- 0Share of holdings soldSold 4.9% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001933414-25-000077, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 11, 2025 | SOpen-market sale Common Stock10b5-1 | -10,758 | $14.45 | $155k | 206,612 | Jul 15, 2025 |
Related signals
Other insiders at Mineralys Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Mineralys Therapeutics, Inc. | Jon Congleton Chief Executive Officer | $1.9M 75,000 shares | -12% | |
| 55Moderate | Mineralys Therapeutics, Inc. | Brian Taylor Slingsby director | $3.0M 104,320 shares | -1% | |
| 12Weak | Mineralys Therapeutics, Inc. | Eric Warren Chief Commercial Officer | $209k 7,438 shares | -16% | |
| 14Weak | Mineralys Therapeutics, Inc. | Daphne Karydas director | $86k 3,000 shares | -33% | |
| 46Moderate | MLYSbuy Mineralys Therapeutics, Inc. | Ra Capital Management, L.p. director | $8.8M 369,000 shares | +7% | |
| 0Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $11k 417 shares | -1% | |
| 4Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $543k 20,406 shares | -23% | |
| 0Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $58k 2,171 shares | -3% | |
| 0Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $12k 417 shares | -1% | |
| 9Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $570k 20,404 shares | -36% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.